Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-Carotegrast Methyl in Healthy Men
NCT03444818Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of firategrast in ulcerative colitis (UC), sponsored by EA Pharma Co., Ltd. Primary endpoints: Maximum concentration of E6007 derived from whole blood at 96 hours, Area under the concentration-time curve from time zero to infinity at 96 hours and 3 more. Started Apr 2018; status: completed.
02
Drugs
firategrast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03444818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444818.